Cardiovascular and Metabolic Disorders Archive
The reduction in risk of cardiovascular death with empagliflozin is most mediated by changes in hematocrit and hemoglobin.
Patients with both gout and diabetes are at a much higher risk for stroke and myocardial infarction than with diabetes alone.
Researchers assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from 14,094 patients.
Future studies using a renin phenotype-driven approach may efficiently identify new-onset or mild hypertension.
Risk of cardiovascular events in people with type 2 diabetes and subgroups of coronary artery disease was examined.
A life-course study evaluated the contribution of vascular endothelial dysfunction and inflammation to the development of hypertension in type 1 diabetes.
Urinary albumin-to-creatinine ratio can be independently associated with various adverse CV outcomes.
In patients with diabetes, coronary artery bypass grafting may be the preferred method of revascularization, with lower rates of major adverse cardiac or cerebrovascular events.
A study sought to clarify whether total physical activity during the day is equally as important as achieving high levels of intensity associated with moderate-to-vigorous physical activity.
Patients with diabetes taking saxagliptin, sitagliptin, second-generation sulfonylureas, pioglitazone, and long-acting insulin were assessed for the risk of acute myocardial infarction.
A strong association was found in study between poor survival in elderly patients with type 2 diabetes and cardiovascular complications, especially heart failure.
Women with hypertensive disorders during pregnancy have a significantly greater risk for future cardiovascular disease when compared with normotensive expecting mothers.
A man presents to the emergency department having had palpitations for the past week, and he has a medical history of hypertension, obesity, and hyperlipidemia. What's the diagnosis?
Cardiovascular disease hospitalization rates have declined in recent years among individuals with and those without diabetes.
Higher childhood body mass index and increases in BMI during childhood are linked to an increased risk of early adult ischemic stroke.
Despite the well‐recognized correlation between weight gain and cardiovascular (CV) disease, there is little direct evidence relating to the impact of insulin‐induced weight gain on CV outcomes.
Increased mortality risks were limited to the first post-HT year because increases in risks markedly decreased when the follow-up time was extended over more than 1 year.
Once-weekly administration of extended-release exenatide in patients with T2D at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.
Empagliflozin lowered the risk of cardiovascular death vs placebo when added to standard of care in adults with both type 2 diabetes and peripheral artery disease.
Levels of high sensitivity C-reactive protein may help risk stratify those patients with T2D and recent acute coronary syndrome at further risk of recurrent cardiovascular events.
Grip strength has clinical utility in identifying people with diabetes at risk for poor health outcomes.
The association between statin use and diabetes risk in a cohort of overweight and obese patients was examined.
Mepsevii replaces beta-glucuronidase, the deficiency of which causes an abnormal buildup of toxic materials in the body's cells.
Investigators encourage further research on the use of NSAIDs in women with preeclampsia who develop postpartum hypertension.
Study aimed to determine the effect of metformin on vascular health in children with T1D and above average weight.
Acarbose, an α-glucosidase inhibitor, decreased the incidence of diabetes in a population with impaired glucose tolerance who were at low risk of cardiovascular events.
People with type 2 diabetes and NOCS-NSTEMI who used incretin had a better prognosis than non-incretin users.
A study confirms whether severe hypoglycemia increases risk for all-cause mortality in patients with type 2 diabetes.
Study revealed heterogeneity in plasma glucose response to oral glucose intake beyond the established glucose criteria based on fasting plasma glucose and 2 h post-load plasma glucose levels.
Researchers assessed the impact of maternal gestational diabetes on insulin resistance and adiposity in adolescent offspring.
Studies have not previously examined long-term risks or mortality after aortic aneurysm or dissection in people with type 2 diabetes.
Study highlights the need to examine the safety of new glucose-lowering treatments specifically in patients with diabetes and heart failure and reduced ejection fraction.
Based on glycemic control and treatment method, type 2 diabetes in the heart failure population can be indicative of various risk associations.
Heart failure prevention may be an opportunity to reduce the risk of death in specific cardiovascular subcategories.
Greater prognostic advantages were associated with high-dose beta blockers in chronic heart failure with diabetes.
The latest ADA hypertension position statement incorporates advances in care since 2003.
PCSK9 inhibition with evolocumab might be an attractive therapy in patients with diabetes, and no discernible effect on glycaemia.
Patients with prediabetes who experienced intensive blood pressure management had better outcomes with CVD events and all-cause mortality.
Results suggest that medication adherence is associated with reduced risk of all-cause mortality in T2D.
BMI measurement alone can also be used to determine associations between childhood and adulthood conditions.
Increasing obesity is associated with increased ICU resource utilization in patients undergoing cardiac surgery.
From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.
Increases in BMI z-score between 7 and 13 years of age increase a person's risk of ischemic stroke in early adulthood.
Hyperglycemia treatment was left to physician's discretion.
The American Academy of Pediatrics released an update to previous hypertension management updates published in 2004.
Patients with MACE showed a greater extent of more severe coronary artery disease.
PCI has been linked to increased risk of CHD, mortality, MI, and repeat revascularization in type 1 diabetes.
More awareness for afib risk factors including age, severity of complications, and glycemic status are needed.
A retrospective analysis examined outcomes in patients with type 2 diabetes treated with SGLT2 vs DPP4 inhibitors.
Researchers created body size phenotypes, defined by BMI category, to assess CVD incidence in a metabolically healthy obese population.
Women with atrial fibrillation and diabetes had a higher risk for mortality and cardiovascular complications compared with men.
Losing weight may result in a decrease of heart muscle thickness.
Patients treated with zoledronic acid vs oral bisphosphonates had higher risk for heart failure and arrhythmias.
An early invasive strategy in patients with non-ST-elevation acute coronary syndromes does not necessarily reduce mortality compared with a delayed strategy.
Multiple clinical studies have examined the efficacy of pitavastatin.
Researchers urge physicians to consider polygenic causes for patients with severe hypertriglyceridemia.
Researchers created 3 plant-based diet indices based on the healthiness of specific foods.
A newly released recommendation statement suggests that physicians should provide lifestyle counseling to both low- and high-risk adults to prevent CVD.
Further investigation is needed to examine the mechanism behind aspirin responsiveness following bariatric surgery.
Compared with insulin glargine, insulin degludec significantly reduced rates of hypoglycemia in patients with either type 1 or type 2 diabetes.
High-dose atorvastatin therapy can reduce inflammation and improve quality of life in patients with severe bronchiectasis and P aeruginosa infection.
Patients with type 2 diabetes who were initiated on insulin therapy increased their sitting time and decreased their low-intensity physical activity.
Dutasteride therapy for benign prostatic hyperlasia has been linked to elevated HbA1c and LDL cholesterol.
Researchers linked all major causes of mortality to childhood intelligence.
N-terminal pro-B-type natriuretic peptide showed the strongest association with heart failure in patients with type 2 diabetes.
Eighty-three veterans with PTSD participated in a study examining biological pathways between PTSD and metabolic diseases.
The least common condition, systemic lupus erythematosus, was associated with the highest association of experiencing multiple cardiometabolic events.
Over 37,000 men were tracked from ages 8 to 20 to examine the link between adolescent BMI and stroke risk.
Left ventricular function can be improved, but not normalized, in adolescents with type 1 diabetes.
Two-hour postload glucose better predicted cardiovascular events compared with fasting plasma glucose and HbA1c.
Metabolic Profile, Weight Increases Assessed in Ziprasidone Augmentation for Major Depressive Disorder
Escitalopram plus ziprasidone was found safe in certain patients, although the therapy required regular cardiovascular and metabolic monitoring.
Data from a UK cohort were used to examine the relationship between maternal sugar intake levels and pediatric respiratory and atopic outcomes.
Pregnancy-associated stroke risk is even higher in women with chronic hypertension, coagulopathies, and prothrombotic conditions.
Researchers examined the efficacy of aspirin in preventing preterm preeclampsia in women at risk.
Financial data for both mothers and children were examined through the first year of life.
Comorbidities included hyperlipidemia, hypertension, and type 2 diabetes, among others.
Extent and severity of coronary artery disease was examined in over 900 patients with type 2 diabetes.
Over 200 patients participated in the study of a novel immunoassay used to distinguish hypertension from hyperaldosteronism.
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
Statin and aspirin therapies in diabetes did not increased patients' risks of cardiovascular events.
Data from the 9300 patient LEADER trial is now eligible for inclusion on liraglutide injection packaging.
Patients with lower vitamin D levels had higher cIMT and were at elevated risk for cardiovascular conditions.
Although metformin did not improve glycemic control in patients with type 1 diabetes, the treatment did improve cardiovascular disease risk management.
Updates to the US Preventive Services Task Force's recommendations on obesity screening in children and adolescents focus on intensive behavioral interventions.
Widely promoted as healthy, coconut oil can increase LDL cholesterol levels similar to other saturated fats.
For patients with type 2 diabetes, visit-to-visit variability in systolic blood pressure may function as an independent predictor for cardiovascular events.
The most effective approaches to CVD self-management were tailored to individual patient needs and incorporated a multidisciplinary approach.
Researchers presented data from the ODYSSEY DM Insulin and Dyslipidemia trials at ADA 2017.
Cardiometabolic Disease Staging scores can be used to quantify diabetes risk and assess efficacy of weight loss pharmacotherapy in obesity.
According to Journal of the American Heart Association, pregnant women with chronic hypertension using antihypertensive agents reduces the risk of hypertension without added risk to the fetus.
The FDA is poised to review data from the DEVOTE trial, examining the rates of major adverse cardiovascular events in insulin degludec vs insulin glargine.
Patients with metabolic syndrome experienced an increase in Unified Parkinson's Disease Rating Scale (UPDRS) scores.
Researchers suggest that women with overweight or obesity aim to lose weight before becoming pregnant.
The role of cholesterol in Parkinson's disease is not well understood.
Two studies examined the effects of naltrexone/bupropion on weight loss, glycemic parameters, and cardiovascular risks in patients with type 2 diabetes.
Patients with type 2 diabetes taking statins after insulin initiation had better glycemic control, but their risk for mortality was higher compared with patients who did not take statins.
Riser patterns in patients' BP resulting from orthostatic hypotension has been linked to increased rates of mortality and major adverse cardiac and cerebrovascular events.
Low-Carbohydrate vs Low-fat Diet Success In Patients With Prediabetes Differs According to Fasting Insulin Levels
Fasting plasma glucose, insulin, and insulin sensitivity levels were measured to determine their prognostic value as markers for long-term weight loss.
Researchers conducted a subgroup analysis of the SPRINT clinical trial to determine whether intensive blood pressure treatment outcomes were similar in patients with prediabetes vs normal fasting blood glucose levels.
Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.
Endocrinology Advisor Articles
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- Pregnancy Rates in Women Undergoing IVF With Fresh vs Frozen Embryos
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Increased Risk for Severe Hypoglycemic Events Associated With CV Outcomes
- Osteoporosis Management: Tailoring a Sequenced Treatment Approach
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Gestational Diabetes May Increase Risk for Hypertension, Ischemic Heart Disease, T2D
- Evaluating the Longitudinal Effects of Diabetes on Cognition
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- Case Challenge: Obesity and Shortness of Breath in a 52-Year-Old Man
- Diabetes Mortality Trends in Adults With Low eGFR, No Albuminuria
- Patients Report Major Concerns With Physicians